BREAKING NEWS
Ultime News Young Middle-Income Buyers Frustrated As US Home Costs Rise Faster Than Incomes Google News USA - Stock Market Top 3 US Stock Market Stories From This Week - Yahoo Finance Google News USA - Biotech FDA Stock Market News Today — NYSE, NASDAQ & OTC Headlines - Stock Titan Yahoo Finance - Mercati USA How Do the Vanguard S&P 500 Growth ETF and the State Street Small Cap Growth ETF Compare? MerlinTrader Blog Weekly Market Recap & Week Ahead: AI Cash Burn, Oil Shock, Fed Week and FDA AdComs — $SPY $QQQ $XBI Ultime News Zero Hedge Google News USA - Stock Market The August stock-market slump is a myth — so why does Wall Street keep repeating it? - MarketWatch Google News USA - Biotech FDA Unicycive Therapeutics: Two CRLs, One Fixable Problem (NASDAQ:UNCY) - Seeking Alpha Yahoo Finance - Mercati USA How to Create Warren Buffett’s 90/10 Portfolio, But With an 11% Yield Google News USA - Stock Market Wall Street Has Never Seen Stock Buying Like This. History Says It Won’t End Quietly - 24/7 Wall St. Google News USA - Biotech FDA Prime Medicine, Inc. (PRME) Stock Price, News, Quote & History - Yahoo! Finance Canada Yahoo Finance - Mercati USA SCHH vs RWR: Which REIT ETF Fits Your Portfolio Google News USA - Stock Market Dow Jones Futures: Market Triggers Sell Signal; Apple Earnings, Iran News, Fed Meeting In Focus - Investor's Business Daily Google News USA - Biotech FDA US-Listed Rare Disease Biotech Hit With Full Clinical Hold; Data Unblinding Ahead - Streetwise Reports Yahoo Finance - Mercati USA Is Cencora (COR) Still Trading At A Discount As Its P E Rerating Gains Pace? Google News USA - Stock Market Stocks waver on Wall Street while crude oil prices fall for the first time in a week - Hartford Courant Google News USA - Biotech FDA CRISPR Therapeutics (CRSP) Enters Phase 1 With CTX112 In Allogeneic CAR T - simplywall.st Yahoo Finance - Mercati USA Dow Jones Futures: Market Triggers Sell Signal; Apple Earnings, Iran News, Fed Meeting In Focus Google News USA - Biotech FDA BridgeBio Oncology Therapeutics, Inc (NASDAQ:BBOT) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat Yahoo Finance - Mercati USA Top 3 US Stock Market Stories From This Week Google News USA - Stock Market The Clock Is Ticking on Wall Street's $1.5 Trillion Powder Keg, and History Says Time Is Almost Up - The Globe and Mail Google News USA - Biotech FDA Is Arcturus Therapeutics' ARCT-032 a Game Changer for Cystic Fibrosis - Kavout | AI Yahoo Finance - Mercati USA VEA vs. SPGM: Which Global Stock ETF Is the Better Buy? Google News USA - Stock Market PDD Stock Faces Wall Street Reset: Temu Expansion, Supply Chain Spending Pressure Outlook - Stocktwits Google News USA - Biotech FDA NanoViricides, Inc. (NNVC) Stock Price, News, Quote & History - Yahoo! Finance Canada Yahoo Finance - Mercati USA Ranking the Best "Magnificent Seven" Stocks to Buy Right Now Google News USA - Stock Market Two Wall Street Analysts Just Set Price Targets on Sandisk $1,430 Apart. One of Them Is Going to Be Very Wrong. - The Motley Fool Google News USA - Biotech FDA Inhibrx Biosciences: The Whole Story Rides On INBRX-106 (NASDAQ:INBX) - Seeking Alpha Yahoo Finance - Mercati USA After Comparing Every Covered Call Nasdaq-100 ETF These 3 Pay Up to 14 Percent Without Capping Your AI Upside Google News USA - Stock Market US Stock Market Weekly Recap: Wall Street Pulls Back Amid Tech Earnings Jitters and Energy Pressures - stl.news Google News USA - Biotech FDA AbbVie (ABBV) Misses Key Phase 3 Survival Goal For Epcoritamab In DLBCL - simplywall.st Yahoo Finance - Mercati USA Global Markets (SPGM) or Emerging Growth (IEMG)? Which Fund is the Right Choice?

Category ONDS

ONDAS INC

Ondas Inc Evolution 2026( $ONDS )

EN IT Ondas, Evolution How ONDS is trying to become a multi-domain defense platform in 2026 — and why the story now looks both more coherent and more demanding than it did just a few months ago. Ticker: ONDS Focus:…

Ondas (NASDAQ: $ONDS) — preliminary 2025 earnings beat and Mistral merger agreement Updated mach 10

A long-form bilingual deep dive on what changed in Ondas’ preliminary fourth-quarter and full-year 2025 update, why the revenue beat matters more than the raw numbers alone, how the Mistral agreement changes the strategic map, and what investors should watch next as ONDS tries to move from fast-growing defense-tech vendor to a broader autonomous systems platform with prime-contractor access.

Ondas ($ONDS) eyes Aeronautics

Onds2026

Israeli business media report that Ondas has submitted an offer to buy Aeronautics, the unmanned systems subsidiary of Rafael. It is a proposal under review, not a completed acquisition. Below: what is confirmed, the political and regulatory risk, and how retail traders are reacting.

ONDS Ondas Inc

In early January we started to follow Ondas Inc. (ONDS) more closely on Merlintrader, first with a long-form deep-dive on the transformation of the group into an autonomous defense “system-of-systems” platform, and then with a sequence of updates as new contracts and Investor Day details emerged. Those articles focused on the structural story, the DCMA “Blue UAS” listing for Optimus and the growing defense pipeline.

Ondas (ONDS) Inc

Ondas Inc. (NASDAQ: ONDS) announced that the Optimus drone from its American Robotics unit has been added to the DCMA “Blue List” of approved unmanned aircraft systems. This confirms compliance with Department of War cybersecurity, supply chain and operational standards and opens a faster lane for U.S. government and defense procurement of Optimus.

At Merlintrader we’ve been following Ondas for a while through this steep progression, and today’s move is another step in the transition from a niche wireless/IoT story towards a more clearly defined dual-use autonomous infrastructure profile.

ONDS Ondas Holdings Inc update jan 17

Why it is a “stock of the moment”
ONDS is one of the most closely watched names in the community: explosive rally, very strong narrative around Israel/defense, and now an Investor Day that pushes the bar even higher with 2026 guidance and very aggressive 5-year targets. It is a classic case where enthusiasm and risk coexist: great to follow, dangerous to underestimate.

ONDS Ondas Holdings Inc jan 8

This is not a buy/sell note, but a way to show readers how Ondas (ONDS) has been covered on Merlintrader over the last months, how the stock moved from November into early January, and what the upcoming Needham Growth Conference presentation actually adds (or doesn’t add) to the picture. Educational only, not investment advice.

ONDS Ondas Holdings Inc jan 06 update

Ondas Holdings (ONDS) has extended its powerful run into early 2026, hitting new four-year highs and moving decisively into mid-cap territory. The next major test for the story is the OAS Investor Day 2026, where management will present the updated 2026 business plan and financial outlook. This update is a companion to the full deep dive available here: ONDS – Ondas Holdings Inc. (full report) .

ONDS Ondas Holdings Inc

2025 performance in the ballpark of +250–270 percent, among the top performers in the defense group.
Growth story tied to autonomous drones and counter-UAS systems in a context of rising defense and security spending.
Very ambitious guidance: management is targeting revenues of at least 36M USD in 2025 and 110M USD in 2026.
Large free float, growing institutional ownership and high volatility: a classic high-beta small cap where newsflow drives big moves.

ONDS Ondas Holdings Update dec 3

2025, Ondas Holdings transformed from a marginal wireless communications company into an emerging leader in autonomous defense, driven by strategic acquisitions, record government contracts, and a rapidly expanding global customer pipeline. With Q3 2025 revenue of $10.1 million, a record backlog of $23.3 million, and an ultra-strong cash position of $840 million, Ondas is exceptionally positioned to capitalize on the boom in the counter-UAS market.